Portal de Periódicos da CAPES

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

2020; Oxford University Press; Volume: 41; Issue: 32 Linguagem: Inglês

10.1093/eurheartj/ehaa500

1522-9645

Charles Fauvel, Orianne Weizman, Antonin Trimaille, Delphine Mika, Thibaut Pommier, Nathalie Pace, Amine Douair, Eva Barbin, Antoine Fraix, Océane Bouchot, O. Benmansour, Guillaume Godeau, Yasmine Mecheri, Romane Lebourdon, Cédric Yvorel, Michael Massin, Tiphaine Leblon, Chaima Chabbi, Erwan Cugney, Léa Benabou, M Aubry, Camille Chan, Inès Boufoula, Clement Barnaud, L Bothorel, Baptiste Duceau, Willy Sutter, Victor Waldmann, Guillaume Bonnet, Ariel Cohen, Théo Pezel,

COVID-19 and healthcare impacts

Abstract Aims While pulmonary embolism (PE) appears to be a major issue in COVID-19, data remain sparse. We aimed to describe the risk factors and baseline characteristics of patients with PE in a cohort of COVID-19 patients. Methods and results In a retrospective multicentre observational study, we included consecutive patients hospitalized for COVID-19. Patients without computed tomography pulmonary angiography (CTPA)-proven PE diagnosis and those who were directly admitted to an intensive care unit (ICU) were excluded. Among 1240 patients (58.1% men, mean age 64 ± 17 years), 103 (8.3%) patients had PE confirmed by CTPA. The ICU transfer and mechanical ventilation were significantly higher in the PE group (for both P < 0.001). In an univariable analysis, traditional venous thrombo-embolic risk factors were not associated with PE (P > 0.05), while patients under therapeutic dose anticoagulation before hospitalization or prophylactic dose anticoagulation introduced during hospitalization had lower PE occurrence [odds ratio (OR) 0.40, 95% confidence interval (CI) 0.14–0.91, P = 0.04; and OR 0.11, 95% CI 0.06–0.18, P < 0.001, respectively]. In a multivariable analysis, the following variables, also statistically significant in univariable analysis, were associated with PE: male gender (OR 1.03, 95% CI 1.003–1.069, P = 0.04), anticoagulation with a prophylactic dose (OR 0.83, 95% CI 0.79–0.85, P < 0.001) or a therapeutic dose (OR 0.87, 95% CI 0.82–0.92, P < 0.001), C-reactive protein (OR 1.03, 95% CI 1.01–1.04, P = 0.001), and time from symptom onset to hospitalization (OR 1.02, 95% CI 1.006–1.038, P = 0.002). Conclusion PE risk factors in the COVID-19 context do not include traditional thrombo-embolic risk factors but rather independent clinical and biological findings at admission, including a major contribution to inflammation.